Adipotide (FTPP) for Fat Loss
An investigational proapoptotic peptidomimetic that targets the blood supply of white fat; it produced weight loss in obese primates but caused reversible kidney effects, and human data are limited to a single early-phase safety study.
Why Adipotide (FTPP) for fat loss?
According to PubMed, adipotide induced targeted apoptosis in white-fat blood vessels and produced rapid weight loss and improved insulin resistance in obese Old World monkeys, but at higher doses caused predictable, reversible renal proximal-tubule changes (Barnhart KF et al., Sci Transl Med 2011). Human data are limited to a Phase 1 dose-finding/safety study (NCT01262664) in patients with obesity and metastatic prostate cancer; development has not advanced publicly. It is investigational only.
Fat Loss context: Reducing body fat percentage through appetite regulation, lipolysis, or metabolic upregulation. Adipotide (FTPP) fits this goal because its category (Metabolic) and benefit profile align with the underlying mechanism.
Benefits relevant to fat loss
- Preclinical: targeted destruction of white-fat vasculature causing fat loss
- Preclinical: weight loss and improved insulin resistance in obese monkeys
- Mechanistically distinct from appetite-based fat-loss agents
Reference dosing by bodyweight
Anchored to the most-cited research dose (3000 mcg @ 75 kg). Reference only.
| Bodyweight band | Reference dose range |
|---|---|
| <60 kg / <132 lb | 1870–2530 mcg |
| 60–75 kg / 132–165 lb | 2295–3105 mcg |
| 75–90 kg / 165–198 lb | 2805–3795 mcg |
| 90–105 kg / 198–231 lb | 3315–4485 mcg |
| >105 kg / >231 lb | 3825–5175 mcg |
Side effects to weigh against fat loss benefit
- Reversible kidney (renal proximal tubule) dysfunction at higher doses
- Injection-site effects
- Long-term human safety unknown
Educational use only
This calculator is provided for research and educational purposes. Outputs are derived from the values you enter. Always verify your math and consult a licensed physician before acting on any result.